Cytokine status in patients with psoriasis

Objective — to study the cytokine status in patients with psoriasis during treatment with azoximer bromide.Materials and methods. In order to study the features of the clinical course and immune status of patients with psoriasis, as well as to assess the effectiveness of the proposed treatments compared to traditional treatment regimens, an open randomized prospective study was conducted. It involved 42 men and 25 women with the most frequently diagnosed forms of the disease: vulgar — in 29 (43.3 %), exudative — in 12 (17.9 %), arthropathic — in 17 (25.4 %), erythrodermic — in 9 (13.4 %) patients. Groups randomized by age and form of psoriasis were formed: group I consisted of 36 patients (standard treatment); group II — 31 patients (combination of standard treatment with azoximer bromide); group III (control) — 22 healthy donors.Results and discussion. The initial content of interleukin (IL)-2 in the serum of patients was heterogeneous, the severity of the disorders depended on the clinical form of dermatosis. Almost all forms of psoriasis showed a significant decrease in the content of IL-2 compared with indices of patients in the control group (p < 0.05). After treatment, a significant increase in IL-2 was observed only in patients with vulgar and exudative forms of psoriasis, while in patients with arthropathic and erythrodermic forms IL-2 remained significantly reduced compared with the indices of patients of the control group. However, IL-2 showed certain increase in some forms of psoriasis. The use of azoximer bromide in complex therapy contributed to a significant reduction in the level of tumor necrosis factor alpha in almost all forms of psoriasis.Conclusions. Patients with psoriasis show significant deviations in cytokine status, which cause dysfunction of the immune system, i.e. the occurrence of complications and chronicity of the psoriatic process. Cytokines are produced by many cells of innate and acquired immunity and their importance directly affects the choice of targeted therapy for particularly severe forms of psoriasis. Carrying out standard therapy for psoriasis in combination with the immunomodulatory drug azoximer bromide contributes to the normalization of the studied pro and anti-inflammatory cytokines, which is manifested by the positive dynamics of not only skin but also joint syndrome. Due to the use of azoximer bromide we marked activation of both Th 1st and Th 2nd way of regulation of the immune system, which indicates an adequate interaction of cellular and humoral parts of the immune system.

Hali tarjima qilinmagan